Home › Osteoarthritis › NCT07430085
Post-Operative Pain Relief: Zynrelef or Periarticular Injections in RATKA
Postoperative Pain Outcomes After Use of Bupivacaine-Meloxicam Extended-Release Solution in Robot Assisted Total Knee Arthroplasty: A Prospective Study
Who can join
Ages 18 to 89 · All sexes
Full eligibility criteria
Inclusion Criteria: Males or females aged 18-89 years Diagnosed with knee osteoarthritis requiring surgical intervention Indicated for unilateral RATKA Exclusion Criteria: Pediatric, pregnant, or incarcerated patients BMI of more than 45 kg/m2 Prolonged opioid use history of \>5 mg/day for \>1 month History of contralateral TKA \<2 years prior to the index TKA Type 1 Hypersensitivity to NSAIDs or local anesthetics Diagnosis of severe renal disease
About the study
Prospective Cohort of patients who are scheduled for a Robot Assisted Total Knee Arthroplasty (RATKA). A prospective survey of patient reported outcome measures (Numeric Rating Scale) will be obtained postoperatively of 72 hours, as well as at the postoperative opioid consumption after 72 hours.
What is being tested
- bupivacaine-meloxicam (extended release) (combination product)
- Bupivacaine (drug)
- Ketorolac (drug)
- Lidocaine (drug) (drug)
Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Participants: 150 · Started: Sep 3, 2026
Contact the study team
- Obinna Ajah, MD · Phone: 877-660-6777
Official record on ClinicalTrials.gov — NCT07430085
Locations in the U.S.
| Pennsylvania | AHN Orthopedic Surgery Cranberry Township, Cranberry Township |
Conditions
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.